Cutaneous Squamous Cell Carcinoma in a Kidney Transplant Recipient: Cancer Control Against Graft Survival
A single patient carrying two competing organs' worth of risk in one decision — a transplanted kidney that has worked for twelve years, and an aggressive skin cancer that has run out of other options. The disagreement is genuinely unresolved: neither position is wrong about what it's protecting.
H.N., a 68-year-old man, has spent the past several years as his wife's primary caregiver as her dementia has progressed, a role that leaves him reluctant to consider anything that would take him out of the house for long. He received a deceased-donor kidney transplant twelve years ago for polycystic kidney disease and has maintained excellent graft function since on tacrolimus and mycophenolate. Over the past eighteen months, a scalp lesion that started as what he assumed was a stubborn actinic keratosis grew into an extensive, ulcerated cutaneous squamous cell carcinoma, now deemed unresectable given its size and proximity to underlying bone; it progressed through a course of radiation and a trial of cetuximab, leaving systemic options limited.
Chronic immunosuppression is the single strongest known risk factor for aggressive cutaneous SCC, and solid organ transplant recipients develop it at rates many times that of the general population — which is precisely what makes cemiplimab, an anti-PD-1 antibody with real, substantial activity in cSCC, both an obvious next option and a genuinely dangerous one for him specifically. Transplant recipients were excluded from EMPOWER-CSCC-1, the pivotal cemiplimab trial in cutaneous squamous cell carcinoma, so the response rates that make it attractive for him were established in patients whose immune systems were not being deliberately suppressed, and pooled retrospective series — the largest aggregating ninety solid organ recipients treated with checkpoint inhibitors for advanced skin cancer — put acute rejection at roughly thirty-eight to forty-two percent, with about six in ten of those rejections going on to graft loss. Small prospective series in which maintenance immunosuppression was deliberately modified before the first dose have reported considerably lower rates, which is so far the only lever anyone has shown moves that number.
TUMORAPA, the one randomized trial of immunosuppression conversion in this population, addressed a different question again — preventing new skin cancers, not treating an established one. His creatinine today sits at his own long-standing baseline of 1.3, a number that tells the team his graft is currently healthy — and gives no information at all about whether it would stay that way if his immune system were unleashed against the very mechanism keeping it in his body. His most recent protocol biopsy, performed eight months ago as part of routine transplant surveillance, showed no chronic rejection and no interstitial fibrosis — which establishes that the graft was healthy going into this, and nothing beyond that. Nothing in his chart, that biopsy included, measures how a kidney tolerated for twelve years behaves once the tolerance is deliberately lifted.
Two organs, one decision
Checkpoint inhibitors in transplant recipients carry a documented acute rejection rate in the range of thirty to forty percent across reported case series, and a meaningful fraction of those end in graft loss. He's had this kidney for twelve years. I'd want every reasonable alternative genuinely exhausted before we take on that risk — starting with converting his immunosuppression toward an mTOR inhibitor, which has its own real anti-cancer activity in exactly this population.
I'm not dismissing that risk. I'm weighing it against the fact that his cancer has already progressed through radiation and through cetuximab, and cemiplimab's response rate in cutaneous SCC is substantially higher than anything else left on the table for him. At some point 'exhaust every alternative first' runs into the reality that his disease isn't waiting for us to work through a sequence.
I take the mTOR conversion argument seriously as an option worth trying — I just don't think it's fast enough, on its own, for disease this advanced and this close to bone, to be worth delaying the treatment most likely to actually control it.
I don't think this has to be resolved as checkpoint-versus-nothing. I want to be careful about what the sirolimus evidence actually covers. TUMORAPA — Euvrard's NEJM trial, with Dantal's five-year follow-up — showed conversion prevents new squamous cell cancers in kidney transplant recipients. It was a secondary-prevention trial. Nobody has shown conversion shrinks an established, unresectable tumor that has already progressed through radiation and cetuximab, and I'm not going to pretend otherwise about a lesion sitting on his skull.
So I'd stop treating conversion as an alternative to cemiplimab and start using it as the thing that makes cemiplimab survivable. Convert him to sirolimus now — that is the immunosuppression modification the lower-rejection prospective series were built around — and start cemiplimab on top of it rather than six to eight weeks behind it. His cancer has already told us it doesn't wait. The rejection risk is the part we can still change.
Agreed: convert his immunosuppression from tacrolimus to sirolimus and start cemiplimab on that modified regimen rather than after a waiting period, on the basis that conversion's evidence is for lowering rejection risk and for preventing new skin cancers, not for treating the tumor he already has.
Not agreed, and left explicitly open rather than smoothed over: how much tumor growth during that six-to-eight-week window would count as 'inadequate response' justifying the move to checkpoint blockade — the Medical Oncologist wanted a firm size threshold set today, the Transplant Nephrologist preferred a clinical judgment made jointly at the follow-up visit rather than a number fixed in advance. Neither position was overruled; the threshold conversation was deferred to the actual follow-up rather than decided today.